BackCastle Biosciences Overview

Castle Biosciences Receivables

Track Castle Biosciences's receivables ($42M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$42.26M
↓ 25.00% YoYΔ $-14.09M vs prior year quarter

Peer average

Loading

Castle Biosciences Receivables History

Loading

Castle Biosciences vs. peers: Receivables Comparison

Loading

Castle Biosciences Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Castle Biosciences (CSTL) FAQ

Castle Biosciences (CSTL) currently reports a receivables of $42M as of March 2026. That compares with $56M in the prior-year period — down 25.0% year over year. Use the charts on this page to explore Castle Biosciences's receivables history and peer comparisons.

Castle Biosciences's receivables decreased from $56M to $42M — a 25.0% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Castle Biosciences reported $42M in receivables as of March 2026. That compares with $56M in the prior-year period — down 25.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $42M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Castle Biosciences, and consider following CSTL for alerts when major investors trade the stock.

Castle Biosciences is classified in the Healthcare sector. On receivables, it currently shows $42M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CSTL with unrelated industries.